Company Research Report: Pfizer Inc.

Company Overview

Name: Pfizer Inc.

Mission Statement: Pfizer is relentlessly pursuing scientific breakthroughs and revolutionary medicines to create a healthier world for everyone.

Founding Information: Founded by Charles Pfizer and Charles Erhart in 1849 in Brooklyn, NY.

Key People:

Dr. Albert Bourla - Chairman and Chief Executive Officer

Andrew Baum, BM ChB - Chief Strategy and Innovation Officer, Executive Vice President

Chris Boshoff, FRCP, FMedSci, Ph.D - Chief Oncology Officer, Executive Vice President

Alexandre de Germay - Chief International Commercial Officer, Executive Vice President

Dave Denton - Chief Financial Officer and Executive Vice President

Mikael Dolsten, M.D., Ph.D. - Chief Scientific Officer, President, Pfizer Research & Development

Headquarters: No specific location provided; past headquarters included Manhattan, NY.

Number of Employees: No information is available.

Revenue: No specific revenue information is provided.

Company Highlights: Pfizer is known for its innovation in biotechnology and pharmaceutical development, notably making significant contributions to healthcare, including the development of the COVID-19 vaccine.

Products

Product Overview

Pfizer offers a wide range of products across various therapeutic areas, including:

Vaccines (e.g., Comirnaty): A focus on immunization against diseases like COVID-19, meningococcal infections, and respiratory syncytial virus (RSV).

Oncology (e.g., IBRANCE, LORBRENA): Treatments for various cancers aiming to prolong patient life and improve quality of life.

Internal Medicine (e.g., ELIQUIS): Medications for cardiovascular health.

Rare Diseases (e.g., VYNDAQEL): Specialty treatments targeting rare and often genetic disorders.

Anti-Infectives (e.g., ZITHROMAX): Antibiotics and antiviral medications developed to combat infections.

Key Product Features

Comirnaty (COVID-19 Vaccine): Pfizer’s flagship COVID-19 vaccine, developed in collaboration with BioNTech, has significantly impacted public health.

IBRANCE (palbociclib): A targeted therapy for certain types of breast cancer, used in combination with other medications.

ELIQUIS (apixaban): An anticoagulant medication widely prescribed to prevent blood clots and reduce stroke risk.

VYNDAQEL (tafamidis meglumine) Capsules and VYNDAMAX: Drugs used for the treatment of transthyretin-mediated amyloidosis.

ZITHROMAX (azithromycin): A broad-spectrum antibiotic used for various bacterial infections.

Recent Developments

Corporate Developments:

PfizerForAll Initiative: Launched as a new platform to simplify healthcare access for Americans, addressing healthcare needs such as migraine, COVID-19, and flu.

Product and Research Progress

New Product Approvals:

ABRYSVO: Approved as an RSV vaccine for adults aged 18 to 59 with increased disease risk.

HYMPAVZI: Cleared by U.S. FDA for treating hemophilia A or B without inhibitors in adults and adolescents.

Noteworthy Trials:

TALZENNA in combination with XTANDI: Demonstrated prolonged overall survival in prostate cancer during Phase 3 TALAPRO-2 trials.

Partnerships & Collaborations:

Partnerships:

American Cancer Society's "Change the Odds": A partnership initiative to improve cancer outcomes.

Valneva on Lyme Disease Vaccine: Collaboration for the development of a potential vaccine addressing risks associated with Lyme disease.

Gavi, the Vaccine Alliance: Achieved the milestone of providing one billion pneumococcal conjugate vaccine doses for child immunization.

This report reflects the latest known successes and ongoing ambition at Pfizer to leverage innovation and partnerships in advancing global health. Please note, for detailed financial and operational insights, direct access to Pfizer's financial statements and related corporate documents would be necessary.

pfizer